Evommune (EVMN) Net Income towards Common Stockholders (2024 - 2026)

Evommune (EVMN) has 3 years of Net Income towards Common Stockholders data on file, last reported at -$113.6 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 677.38% year-over-year to -$113.6 million in Q1 2026; TTM through Mar 2026 was -$168.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$132.3 million, down 95.72% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$113.6 million, down from -$27.9 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for EVMN reached as high as -$12.5 million in Q3 2025 and fell as low as -$113.6 million in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged -$34.1 million across 3 years, with a median of -$18.0 million in 2024.
• Across the five-year window, Net Income towards Common Stockholders increased 21.62% in 2025 and slumped 677.38% in 2026, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$20.2 million in 2024, then tumbled by 38.27% to -$27.9 million in 2025, then tumbled by 307.62% to -$113.6 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$113.6 million in Q1 2026, -$27.9 million in Q4 2025, and -$12.5 million in Q3 2025.